Latest Information Update: 05 Apr 2016
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; National Cancer Institute (USA)
- Class Antineoplastics
- Mechanism of Action Tropomyosin-related kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma